Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800

Endocrinology

Volumn 138, Issue 12, 1997, Pages 5605-5617

  Sourla, Antigone ^a   Luo, Shouqi ^a   Labrie, Claude ^a   Bélanger, Alain ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030711496     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.138.12.5560     Document Type: Article

References (68)

1. Chu KC, Tarone RE, Kessler LG, Ries LAG, Hankey BF, Miller BA, Edwards BK 1996 Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:1571-1579
2. Devesa SS, Silverman DT, Young Jr JL, Pollack ES, Brown CC, Horm JW, Percy CL, Myers MH, McKay FW, Fraumeni Jr JF 1987 Cancer incidence and mortality trends among whites in the United States. J Natl Cancer Inst 79:701-770
3. Parker SL, Tong T, Bolden S, Wingo PA 1997 Cancer statistics 1997. CA 45:5-27
4. Asselin J, Kelly PA, Caron MG, Labrie F 1977 Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 101:666-671
5. Dickson RB, Lippman ME 1987 Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29-43
6. Horwitz KB, McGuire WL 1978 Nuclear mechanism of estrogen action. Effect of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem 253:8185-8191
7. Mouridsen H, Palshof T, Patterson J, Battersby L 1978 Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131-141
8. 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46:4933-4937
9. Rochefort H, Garcia M 1983 The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 23:193-216
10. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL 1996 Five vs. more than five years of Tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors. J Natl Cancer Inst 88:1529-1542
11. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H 1981 Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1-6
12. Kiang DT, Kennedy BJ 1977 Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med 87:687-690
13. Swedish Breast Cancer Cooperative Group 1996 Randomized trial of two vs. five years of adjuvant Tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549
14. Friedl A, Jordan VC 1994 What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 31:27-39
15. Furr BJ, Jordan VC 1984 The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205
16. Lippman M, Bolan G, Huff K 1985 Cancer Res 45:584-590
17. Osborne CK, Hobbs K, Clark GM 1985 Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590
18. Gottardis MM, Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187
19. Osborne CK, Coronado Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-50
20. Wakeling AE, Bowler J 1988 Biology and mode of action of pure antiestrogens. J Steroid Biochem 30:141-147
21. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
22. Labrie C, Martel C, Dufour JM, Lévesque C, Mérand Y, Labrie F 1992 Novel compounds inhibit estrogen formation and action. Cancer Res 52:610-615
23. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F 1991 Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N, n-butyl-N-methyl-11-(16′α-chloro-3′, 17β-dihydroxy-estra-1′, 3′, 5′-(10′)triene-7′α-yl)undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 51:2797-2802
24. Lévesque C, Mérand Y, Dufour JM, Labrie C, Labrie F 1991 Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 34:1624-1630
25. Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F 1991 Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 51:3131-3135
26. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F 1997 (S)-(+)-[4-[7-(2, 2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1- benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J Med Chem 40:2117-2122
27. Simard J, Labrie C, Bélanger A, Gauthier S, Singh SM, Mérand Y, Labrie F, Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced prolieration of T-47D, ZR-75-1 and MCF-7 human breasts cancer cells in vitro. Int J Cancer, in press
28. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Mérand Y, Bélanger A, Labrie C, Labrie F 1997 Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 57:3494-3497
29. Luo S, Martel C, Sourla A, Gauthier S, Mérand Y, Bélanger A, Labrie C, Labrie F, Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int J Cancer, in press
30. Carson FL 1990 In: Borysewicz S (ed) Histotechnology. A Self-Instructional Text. ASCP Press, Chicago, 308 pp
31. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
32. Kramer CY 1956 Extension of multiple range tests to group means with unique numbers of replications. Biometrics 12:307-310
33. Le Bouedec G, Dauplat J 1992 Cancer of the endometrium caused by antiestrogens. Rev Fr Gynecol Obstet 87:345-348
34. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G 1990 Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37:378-380
35. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E 1992 Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36:127-130
36. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, Campanella G, Gaggero G, Comelli G, Zanardi S, Nicolo G 1984 Endocrine effects of tamoxifen in post-menopausal breast cancer patients. Tumori 70:61-68
37. Jordan VC, Lababidi MK, Mirecki DM 1990 Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer 26:718-721
38. Tang FY, Bonfiglio TA, Tang LK 1984 Effect of estrogen and progesterone on the development of endometrial hyperplasia in the Fischer rat. Biol Reprod 31:399-413
39. Branham WS, Zehr DR, Sheehan DM 1993 Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc Soc Exp Biol Med 203:297-303
40. Terenius L 1971 Structure-activity relationships of anti-oestrogens with regard to interaction with 17β-oestradiol in the mouse uterus and vagina. Acta Endocrinol (Copenh) 66:431-447
41. Lu YC, Chatterton Jr RT 1994 Effect of anordiol on ovarian hormone secretion, ovulation, and uterine and vaginal responses in the immature rat. Adv Contracept 10:157-166
42. Ugwumadu AH, Harding K 1994 Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen. Eur J Obstet Gynecol Reprod Biol 54:153-156
43. Lumsden MA, West CP, Hillier H, Baird DT 1989 Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)-lack of shrinkage of uterine fibroids. Fertil Steril 52:924-929
44. Kadaba R, Simpson CW 1990 Disparate effect of tamoxifen in rats with experimentally induced endometriosis. Endocrinology 126:3263-3267
45. Jordan VC 1984 Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245-276
46. Katzenellenbogen BS, Bhakoo HS, Ferguson ER, Lan NC, Tatee T, Tsai TS, Katzenellenbogen JA 1979 Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res 35:259-300
47. Kalu DN, Salerno E, Liu CC, Echon R, Ray M, Garza Zapata M, Hollis BW 1991 A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 15:109-123
48. Chou YC, Iguchi T, Bern HA 1992 Effects of antiestrogens on adult and neonatal mouse reproductive organs. Reprod Toxicol 6:439-446
49. Hardell L 1988 Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 3:563
50. Killackey MA, Hakes TB, Pierce VK 1985 Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237-238
51. Neven P, DeMuylder X, VanBelle Y 1989 Tamoxifen and the uterus and endometrium. Lancet 1:375
52. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolse VA 1992 Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 79:111-116
53. Kangas L 1992 Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31:143-146
54. Jordan VC, Robinson SP 1987 Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 46:1870-1874
55. Maenpaa J, Soderstrom KO, Gronroos M, Taina E, Hajba A, Kangas L 1990 Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women. J Steroid Biochem 36:221-223
56. Boccardo F, Bruzzi R, Rubagotti BZ, Nicolo GU, Rosso R 1981 Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281-285
57. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M 1977 Oestrogen-like effect of tamoxifen on vaginal epithelium. Br Med J 1:1351-1352
58. Eells TP, Alpern HD, Grzywacz C, MacMillan RW, Olson JE 1990 The effect of tamoxifen on cervical squamous maturation in Papanicolaou stained cervical smears of post-menopausal women. Cytopathology 1:263-268
59. Boorman GA, Eustis SL, Elwell MR, Montgomery Jr CA, Mackenzie WF 1990 Pathology of the Fisher Rat. Reference and Atlas. Academic Press, San Diego, CA, pp 433
60. Korach KS 1994 Insights from the study of animals lacking functional estrogen receptor. Science 266:1524-1527
61. Dukes M, Chester R, Yarwood L, Wakeling AE 1994 Effects of a non-steroidal pure antioestrogen ZM 189,154, on oestrogen target organs of the rat including bones. J Endocrinol 141:335-341
62. Proulx-Ferland L, Lépine J, Labrie F, Stimulation of peptide release from the anterior, and intermediate lobes of the pituitary gland by a central action of opiates. Proceedings of the 5th Canadian College of Neuropsychopharmacology Annual Scientific Meeting, Quebec, 1982 (Abstract 21)
63. Labrie F 1991 Intracrinology. Mol Cell Endocrinol 78:C113-C118
64. Roy AK 1992 Regulation of steroid hormone action in target cells by specific hormone-inactivating enzymes. Proc Soc Exp Biol Med 199:265-272
65. Luu-The V, Labrie C, Zhao HF, Couët J, Lachance Y, Simard J, Leblanc G, Côté J, Bérubé D, Gagné R, Labrie F 1989 Characterization of cDNAs for human estradiol 17β-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5′ termini in human placenta. Mol Endocrinol 3:1301-1309
66. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Bélanger A 1997 The key role of 17β-HSDs in sex steroid biology. Steroids 62:148-158
67. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G, Morel Y, Mebarki F, Sanchez R, Durocher F, Turgeon C, Labrie Y, Rhéaume E, Labrie C, Lachance Y 1996 The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Hansson V, Levy FO, Taskén K (eds) Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop. Springer-Verlag, Berlin, Supplement 2, pp 185-218
68. Nicholson RJ, Gotting KE, Gee J, Walker KJ 1988 Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. J Steroid Biochem 30:95-103